Moderna, Inc. vs VNET Group Inc — how do they compare? Moderna, Inc. trades at $60.45 (market cap $24.18B), while VNET Group Inc trades at $7.54 (market cap $2.14B). The key difference: Moderna, Inc. is far larger — about 11.3× VNET Group Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | VNET | |
|---|---|---|
Market Cap | $24.18B | $2.14B |
Sector | Health | Technology |
52-Week High | $81.80 | $14.03 |
52-Week Low | $22.36 | $6.29 |
Enterprise Value | $20.33B | $5.29B |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
No Aura AI signal available yet.
Trailing returns across standard periods
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →